147 related articles for article (PubMed ID: 14616052)
1. Respiratory syncytial virus (RSV) as a common cause of respiratory illness in children younger than 5 years.
Poehling KA; Hickson GB
Ambul Pediatr; 2003; 3(6):342-4. PubMed ID: 14616052
[No Abstract] [Full Text] [Related]
2. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
Robinson RF; Nahata MC
Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus: concerns and control.
McCarthy CA; Hall CB
Pediatr Rev; 2003 Sep; 24(9):301-9. PubMed ID: 12949266
[No Abstract] [Full Text] [Related]
4. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
Huang K; Wu H
Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
[TBL] [Abstract][Full Text] [Related]
5. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
6. Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease.
Taylor G; Porter T; Dillon S; Trill J; Ganguly S; Hart T; Davis C; Wyde P; Tempest P; Harris W
Biochem Soc Trans; 1995 Nov; 23(4):1063-7. PubMed ID: 8654682
[No Abstract] [Full Text] [Related]
7. Management of respiratory syncytial virus infection.
Kimpen JL
Curr Opin Infect Dis; 2001 Jun; 14(3):323-8. PubMed ID: 11964851
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against respiratory syncytial virus.
Givner LB
Pediatr Infect Dis J; 1999 Jun; 18(6):541-2. PubMed ID: 10391187
[No Abstract] [Full Text] [Related]
9. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
10. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
[TBL] [Abstract][Full Text] [Related]
11. Preventing respiratory syncytial virus (RSV) disease in children.
Karron RA
Science; 2021 May; 372(6543):686-687. PubMed ID: 33986169
[No Abstract] [Full Text] [Related]
12. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
13. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation.
Shah JN; Chemaly RF
Blood; 2011 Mar; 117(10):2755-63. PubMed ID: 21139081
[TBL] [Abstract][Full Text] [Related]
14. Management of infections caused by respiratory syncytial virus.
Swedish Consensus Group
Scand J Infect Dis; 2001; 33(5):323-8. PubMed ID: 11440215
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus immune globulin: decisions and costs.
Barton LL; Grant KL; Lemen RJ
Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
[TBL] [Abstract][Full Text] [Related]
16. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
Groothuis JR; Nishida H
Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
[TBL] [Abstract][Full Text] [Related]
17. Strategies for preventing respiratory syncytial virus.
Forbes M
Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
[TBL] [Abstract][Full Text] [Related]
18. Current strategies in the prevention of respiratory syncytial virus disease.
Paes BA
Paediatr Respir Rev; 2003 Mar; 4(1):21-7. PubMed ID: 12615029
[TBL] [Abstract][Full Text] [Related]
19. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
20. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.
Hiatt A; Bohorova N; Bohorov O; Goodman C; Kim D; Pauly MH; Velasco J; Whaley KJ; Piedra PA; Gilbert BE; Zeitlin L
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):5992-7. PubMed ID: 24711420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
